TheraRadar
← Back
Data updated: Mar 29, 2026

FOSUN WANBANG

CardiovascularOncologyGastroenterology
Generics

FOSUN WANBANG is a generic drug manufacturer focused on Cardiovascular, Oncology, Gastroenterology.

2005
Since
4
Drugs
-
Trials
32
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

MYCOPHENOLATE SODIUM 2026-01-14
Labeling
LEFLUNOMIDE 2025-10-24
Labeling
SUNITINIB MALATE 2025-07-22
Manufacturing (CMC)
GUANFACINE HYDROCHLORIDE 2025-04-15
SUNITINIB MALATE 2025-02-14
GUANFACINE HYDROCHLORIDE 2025-02-12
Labeling
MYCOPHENOLATE SODIUM 2024-12-19
Labeling
MYCOPHENOLATE SODIUM 2024-12-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 33%
1 drugs
Oncology 33%
1 drugs
Gastroenterology 33%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Novartis big-pharma
Oncology, Cardiovascular
WAYLIS THERAP big-pharma
Oncology, Cardiovascular, Gastroenterology
Merck big-pharma
Oncology, Cardiovascular
Baxter specialty
Cardiovascular, Oncology